Brief: Matinas Biopharma Announces Unanimous Dsmb Approval To Progress Into Second Cohort Of Patients In The Enact Study Of Mat2203 For The Treatment Of Cryptococcal Meningitis
19/10/2020 11:37
Oct 19 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES UNANIMOUS DSMB APPROVAL TO
PROGRESS
INTO SECOND COHORT OF PATIENTS IN THE ENACT STUDY OF MAT2203
(ORAL AMPHOTERICIN B) FOR THE TREATMENT OF CRYPTOCOCCAL
MENINGITIS
* MATINAS BIOPHARMA HOLDINGS - ENROLLMENT IN SECOND COHORT
OF
PATIENTS EXPECTED TO COMMENCE IMMINENTLY WITH NEXTDSMB
EVALUATION ANTICIPATED MID-2021
Source text for Eikon: ID:nGNX8Y6npR
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing